An interferon y (IFN-y)-inducible protein, y2, was identified by two-dimensional gel electrophoresis of transformed human amnion (AMA) cell proteins. cDNA dones coding for this protein have been isolated and characterized as encoding a polypeptide with a predicted molecular weight of 53,165 and a pI of6. 16 . Both values are in good agreement with those observed in two-dimensional gel dectrophoresis. The y2 protein is found to be highly Induced by UIN-y, whereas no induction was seen after addition f IFN-a to AMA cells. A y2-specilfc 2.7-kilobase mRNA was likewise seen to accumulate selectively in response to IFN-y 
tivity and thus constitutes an enzymatic activity involved in the bioiogical activity of IFN-y.
Interferons (IFNs) are inducible glycoproteins eliciting an antiviral state in target cells (1) . In addition they are potent biomodulators exerting a large number of other effects.
IFN-y (type II IFN) is distinct from IFN-a and IFN-.3 (type I IFNs) molecules on the basis of antigenicity, inducer, primary structure, cell receptor, and producer cells. IFN-y is more effective than type I IFNs in inhibiting proliferation of various malignant cells and cultured cells and in modulating the activity of cells in the immune system (for reviews, see refs. 2 and 3).
Specific sets of proteins are induced in various cell lines after IFN treatment (4) (5) (6) . Addition of IFN-y to various cell lines results in the preferential induction of a set of genes including major histocompatibility complex class II genes (7, 8) , the Fc receptor gene for IgG (9) , 'yIP-10 and m119 [both belonging to the platelet factor 4 family (10, 11) ], phagocyte cytchrome b heavy chain gene (12) , the gene encoding indoleamine 2,3-dioxygenase (13) , and two genes IP-30 and y.1 of unknown functions (14, 15) .
We have previously used two-dimensional gel electrophoresis [isoelectric focusing (IEF) and SDS] to characterize sets ofhuman polypeptides specifically induced by IFN-a/P or by IFN-'y (4) . The cloning of genes of such proteins is an essential step in the analysis ofpathways underlying major or specific effects of IFN action. Here we report on cDNA cloning and expression studies of the y2 protein, which is preferentially and very strongly induced by IFN-y in AMA cells (epithelial) and MRC-5 cells (fibroblast) (4) . The deduced Mr 53,165 amino acid sequence § is highly homologous to that of rabbit peptide chain release factor (16) (18) . The y2 protein purified to -80%o purity (SDS/PAGE estimate) was subjected to two-dimensional gel electrophoresis. The y2 spots were cut from the gels, concentrated by SDS/PAGE, electroblotted onto a ProBlot membrane (Applied Biosystems), and tryptic peptides were subjected to amino acid sequencing on a gas-phase sequencer (Applied Biosystems model 470A) (18 tTo whom reprint requests should be addressed. §The sequence reported in this paper has been deposited in the GenBank data base (accession no. X59892).
MATERIALS AND METHODS
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. mM Tris Cl (pH 8.3), 50 mM KCl, 2 mM MgCl2, 0.1% gelatin, and 0.2 unit of Taq polymerase (Cetus). For the amplification, 40 cycles of denaturation (940C, 1 min), annealing (450C, 1 min), and extension (720C, 3 min) were used.
Construction and Screening of cDNA Library. Twice poly(A)+-selected RNA (5 gg) was prepared from AMA cells that had been exposed to IFN-'y (100 IU/ml) for 4 h or 8 h (pooled). cDNA was synthesized (19) and a library was constructed in Agt1O (20) . Screening was performed by plaque hybridization using a 32P-labeled PCR-derived partial y2
cDNA (see Results).
Sequencing of cDNA Clones. BAL-31 exonuclease (Amersham) deletions of the cDNA clones were inserted into bacteriophage M13 (21) . DNA sequencing of overlapping deletions was done by the dideoxy-nucleotide chaintermination method using reagents from United States Biochemical.
RNA Preparation and Northern Blot Analysis of RNAs. All RNA samples were prepared by the acid guanidinium thiocyanate/phenol/chloroform extraction method (22) . Northern blot analysis was done by electrophoresis of total cellular RNA through 1% formaldehyde/agarose denaturing gels and transfer to Zeta-Probe membranes (Bio-Rad) in lOx SSC (1.5 M NaCI/0.15 M sodium citrate, pH 7.0). Radioactive DNA probes were prepared by random oligonucleotide priming (23) .
Assay for Tryptophan Aminoacyl Synthetase Activity. To test for enzymatic activity of y2 protein the tryptophandependent ATP-pyrophosphate exchange assay (24) was used in a modified form using TLC to identify ATP and pyrophosphate (25 RESULTS Induction of the y2 Polypeptide in AMA Cells. As described (4), IFN-y induces a specific set of polypeptides in AMA cells. The location of y2 in two-dimensional gels of AMA cell proteins in untreated (Fig. 1A) and IFN-y-treated (Fig. 1B) cells is shown. The strongly induced y2 polypeptide has an apparent molecular mass of 55.3 kDa (Figs. 1 and 2 ) and a pI of 5.99 ( Fig. 1) . To study the induction kinetics, AMA cells were pulse-labeled for 1 h at various times after IFN--y addition. At 4-6 h after induction, a 'y2 band became clearly visible, increased dramatically in intensity, and reached a maximum level after 10 h (Fig. 2 ). This high level was maintained for at least 24 h in the presence of IFN-y.
Isolation of y2 cDNA. Amino acid sequences of internal tryptic peptides were obtained by microsequencing of the y2 protein spots excised from two-dimensional gels as described (18 (Fig. 4B) . y2 mRNA was measured relatively to GAPDH mRNA, which is unaffected by IFN treatment.
In various human cell lines, variation in the induction of y2 mRNA by IFN-,y was observed. In MRC-5 and HT1O80 fibroblasts, y2 mRNA was strongly inducible by IFN-'y and unaffected by IFN- Fig. 5 , where y2, peptide chain release factor and tryptophanyl-tRNA synthetase amino acid 1 GAC CAGT GGCCACCT C TGCAGT GTC T TCCACMACC TGG&TCTT GACT CGT CTGC T GAACATCCT CT&ACC TCAGGCCGGCT GT GAAC GTAGT TCCT GAGAGATAGCAACATGCCCAAC 1 M P N 1 21 AGT GAGC CC GCAT CTCT GCTGG&AGCTGT T CACAGCAT CGCCACACAAGGGGAGCT CGTAAGGT CCCT CAGCGGGAATGCGT CAGGAT GAMAT TGAT TCT GCAGTAAAGAT GT TG The GAPDH cDNA was a Pst I fragment subcloned in pUC19, originally derived from pRGAPDH (26 sequences are aligned. v2 displays identity with 94% of the amino aids in-tryptophanyl-tRNA synthetase and with 87% of the amino acids of peptide chain release factor. When conservative amino acid substitutions were considered, similarity rose to 971% and 94% for these sequences, respectively. The region with the highest degree of divergence was the extreme N-terminal region, in which the three proteins differed in length. At position 170, y2 possesses a HIGH amino acid motif as identified in prokaryotic class I tRNA synthetases (Fig. 5 ) (28) . Sequencing of the region around amino acid positions [164] [165] [166] [167] [168] [169] [170] initially resulted in the translated amino acid sequence PLLKQCN. As this sequence can be transformed into that of tryptophanyl-tRNA synthetase by a simple +1 fiameshifting over eight codons, the sequence analysis ofthis Proc. Natl. Acad. Sci. USA 88 (1991) 11523 area was repeated using ITP instead of GTP to resolve any compressions. This analysis indeed revealed a compression around nucleotide 602 adding an extra nucleotide to the sequence, which again was compensated by another sequencing error 21 nucleotides further downstream. The new nucleotide sequence translated into the amno acid sequence PSSEAMH forming part of the HIGH motif (Fig. 5) . Prokaryotic class I amino acid tRNA synthetases are also characterized by the KMSKS amino acid motif, which in combination with the HIGH motif is indiative of the presence of a Rossman fold, thought to be involved in nucleotide binding (29, 30) . In y2 and WRS (and eRF), a C-terminal motif KMSAS homologous to KMSKS was also found (Fig.   5 ).
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Tryptophan-Dependent Amicyl-tRNA Syne Activity of Purified y2 Protein. The 'y2 protein was purified to :900% purity by a series of column chromatography steps including DEAE-cellulose, heparin-Sepharose, and Procion red-Sepharose. The purified fraction was tested for aminoacyl-tRNA synthetase activity using the pyrophosphate exchange assay (24) . Fig. 6A (Fig. 3) . In AMA cells the amount of the y2 polypeptide was found to increase m y upon IFN-'y treatment ( Figs. 1 and 2) as did the level of mRNA (Fig. 4A) , where a 60-fold increase was observed (Fig.   4B) 
9y2 DLDYMGMSSGFYKNVVKIQKHVTFNQVKGI FGFTDSDCI GKI SFPAIQAAPSFSNSFPQ I FRDRTD IQCL IPCAIDQDPYFRNTRDVAPRIGYPKPALLKSTFFPALQGAFPTMAL 4N 356 tRNA synthetase (GenBank accession no. X52113) (Fig. 5 ). This presents a problem since these proteins have different and so far unrelated biological activities. Rabbit peptide chain release factor cDNA was demonstrated to encode a polypeptide with in vitro biological activities of a release factor (16) . The bovine tryptophanyl-tRNA synthetase cDNA has to our knowledge so far only been published in the data base, and detailed information concerning activities of the expressed product is thus not available. Highly purified native y2 protein was demonstrated by pyrophosphate exchange assay to have tryptophanyl-tRNA synthetase activity (Fig.  6 ). We have not tested whether native y2 has release factor activity. The current data raise the possibility that the tryptophanyl-tRNA charging and peptide chain release from the ribosome are functions carried out by the same protein.
Within the cell the y2 protein thus may function as an aminoacyl-tRNA synthetase or as a release factor or possibly as both. Other mediators of the biological activities of IFNs have been shown to target the protein synthesizing machinery (for reviews, see refs. 32 and 33). It is, therefore, fascinating that the y2 protein also seems to be directly involved in protein synthesis. Moreover, it is intriguing that the IFN-'-induced enzyme indoleamine 2,3-dioxygenase also targets tryptophan by being the first enzyme in the degradation pathway oftryptophan (34) leading to a depletion of the cellular tryptophan pool (35, 36) .
Several possibilities can be envisaged to explain how the y2 protein is involved in the biological actions of IFN-y. The simultaneous induction 'of indoleamine 2,3-dioxygenase and y2 does result in a low tryptophan level, which again might favor the release factor function of y2. The high activity of release factor might in turn lead to a frequent premature release of nascent. polypeptide chains froimthe ribosomes, resulting in the accumulation of malfunctioning proteins.
Note. Recently, L. Igisselev has communicated to us that Frolova et al. (37) have cloned a cDNA for human tryptophanyl-tRNA synthetase (GenBank accession no. M61715). This sequence is identical to that of y2 (except for four base differences) but lacks "600 bp at the 3' end. Their cDNA has an additional sequence of "100 bp at the 5' end.
